Species/Strain: Rat/F344

Route: Gavage, IV

Toxicokinetics Data Summary

Test Compound: 2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 11/09/2016 Time Report Requested: 14:00:07

Lab: Research Triangle Institute

Male

_	Treatment Groups (mg/kg)						
	100 ^{a, #}	100 ^{c, #}	100 ^{b, *}	250 a, #	250 b, *	500 ^{a, #}	
		Plasma					
C _{max} (mg/L)	0.220		0.149	0.367	0.454	2.43	
T _{max} (minute)	30		60	90	30	60	
Alpha (min^-1)		0.166 ± 0.019					
Beta (min^-1)	0.0067	0.0055 ± 0.0017		0.0034		0.0037	
i1/2(Beta) (minute)	103			206		186	
k ₀₁ (min^-1)		0.0152 ± 0.0048					
k ₁₀ (min^-1)		0.106 ± 0.015					
k ₁₂ (min^-1)		0.0569 ± 0.012					
k ₂₁ (min^-1)		0.008603 ± 0.0025					
CI (L/min/kg)							
CI _{1(F)} (L/min/kg)	4.56			3.63		1.22	
V ₁ (L/kg)		0.429 ± 0.062					
V _{1(F)} (L/kg)	680			1077		327	
MRT (minute)	150			223		303	
AUC _{0-t} (mg*min/L)			29.4		73.9		
AUC _{inf} (mg*min/L)	23.6			60.8		374	
F (fraction)	0.00835			0.0105		0.0313	

Species/Strain: Rat/F344

Route: Gavage, IV

Toxicokinetics Data Summary

Test Compound: 2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 11/09/2016 Time Report Requested: 14:00:07

Lab: Research Triangle Institute

Male

	Treatment Groups (mg/kg)				
	500 b, *	8 IV ^{a, #}	8 IV b, *		
	Plasma				
C _{max} (mg/L)	1.41	8.57	0.0840		
T _{max} (minute)	60	5	5		
Alpha (min^-1)					
Beta (min^-1)		0.0022			
t _{1/2(Beta)} (minute)		313			
k ₀₁ (min^-1)					
k ₁₀ (min^-1)					
k ₁₂ (min^-1)					
k ₂₁ (min^-1)					
CI (L/min/kg)		0.0381			
CI _{1(F)} (L/min/kg)					
V ₁ (L/kg)		17.2			
V _{1(F)} (L/kg)					
MRT (minute)		77.1			
AUC _{0-t} (mg*min/L)	246		6.86		
AUC _{inf} (mg*min/L)		202			
F (fraction)					

Species/Strain: Rat/F344

Route: Gavage, IV

Toxicokinetics Data Summary

Test Compound: 2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 11/09/2016 Time Report Requested: 14:00:07

Lab: Research Triangle Institute

Female

_		Treatment Groups (mg/kg)					
	100 ^{a, #}	100 ^{d, #}	100 b, *	250 ^{a, #}	250 b, *	500 a, #	
	Plasma						
C _{max} (mg/L)	0.209		0.203	0.391	0.570	2.69	
T _{max} (minute)	60		60	90	30	60	
Alpha (min^-1)		0.0887 ± 0.011					
Beta (min^-1)	0.0060	0.00464 ± 0.0015		0.0062		0.0050	
t _{1/2(Beta)} (minute)	116			112		139	
k ₀₁ (min^-1)		0.0126 ± 0.0035					
k ₁₀ (min^-1)		0.0579 ± 0.0074					
k ₁₂ (min^-1)		0.0283 ± 0.0071					
k ₂₁ (min^-1)		0.00711 ± 0.0023					
Cl (L/min/kg)							
CI _{1(F)} (L/min/kg)	6.14			4.08		1.58	
V ₁ (L/kg)		1.39 ± 0.15					
V _{1(F)} (L/kg)	1020			660		316	
MRT (minute)	175			159		172	
AUC _{0-t} (mg*min/L)			41.8		105		
AUC _{inf} (mg*min/L)	17.4			53.5		286	
F (fraction)	0.0127			0.0190		0.0491	

Species/Strain: Rat/F344

Route: Gavage, IV

Toxicokinetics Data Summary

Test Compound: 2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 11/09/2016 Time Report Requested: 14:00:07

Lab: Research Triangle Institute

Female

_	Treatment Groups (mg/kg)				
	500 b, *	8 IV ^{a, #}	8 IV b,*		
	Plasma				
C _{max} (mg/L)	1.08	3.70	0.121		
T _{max} (minute)	60	5	10		
Alpha (min^-1)					
Beta (min^-1)		0.0038			
t _{1/2(Beta)} (minute)		180			
k ₀₁ (min^-1)					
k ₁₀ (min^-1)					
k ₁₂ (min^-1)					
k ₂₁ (min^-1)					
CI (L/min/kg)		0.0776			
Cl _{1(F)} (L/min/kg)					
V ₁ (L/kg)		20.2			
V _{1(F)} (L/kg)					
MRT (minute)		95.6			
AUC _{0-t} (mg*min/L)	278		12.4		
AUC _{inf} (mg*min/L)		100			
F (fraction)					

Experiment Number: S0593 Toxicokinetics Data Summary

Route: Gavage, IV Test Compound: 2-Hydroxy-4-methoxybenzophenone

Time Report Requested: 14:00:07 **CAS Number:** 131-57-7 Species/Strain: Rat/F344 Lab: Research Triangle Institute

Date Report Requested: 11/09/2016

LEGEND

Data are displayed as mean ± SEM

MODELING METHOD & BEST FIT MODEL

- ^a WinNonlin (Models 200 and 201), Version 1.0 (Scientific Consulting Inc., 1995); Noncompartmental modeling
- ^b WinNonlin Version 1.0 (Scientific Consulting Inc., 1995); Noncompartmental modeling
- ^c WinNonlin Version 1.0 (Scientific Consulting Inc., 1995); Best fit is two compartmental which simultaneously solves iv and oral data sets. Analyzed using compartmental modeling techniques with established models or models written to simultaneously solve iv (Study U) and oral data sets (Study W) using 1/YHAT weighting where YHAT is the predicted plasma HMBP concentration at a given time.

ANALYTE

- [#]2-Hydroxy-4-methoxybenzophenone
- * 2.4-Dihvdroxybenzophenone

TK PARAMETERS

C_{max} = Observed or Predicted Maximum plasma (or tissue) concentration

 T_{max} = Time at which C_{max} predicted or observed occurs

Alpha = Hybrid rate constant of the alpha phase

Beta = Hybrid rate constant of the beta phase

 $t_{\frac{1}{2}(\text{beta})}$ = Half-life for the beta phase

 k_{01} = Absorption rate constant, k_a

 k_{10} = Elimination rate constant from the central compartment also k_e or k_{elim}

 k_{12} = Distribution rate constant from first to second compartment etc.

 k_{21} = Distribution rate constant from second to first compartment etc.

CI = Clearance, includes total clearance

 $Cl_{_{1/E}}$ = Apparent clearance of the central compartment, also $C_{l(F)}$ for gavage groups in non-compartmental model

V₁ = Volume of distribution of the central compartment, includes V_d and V_{volume} of distribution, V_z apparent volume of distribution NCA,

V_{app} apparent volume of distribution for intravenous studies

 $V_{1(F)}$ = Apparent volume of distribution for the central compartment includes $V_{d(F)}$, $V_{(F)}$ for oral groups, and $V_{c(F)}$

MRT = Mean residence time

 $AUC_{0-t} = Area under the plasma concentration versus time curve, AUC, from time t_i (initial) to t_f (final), <math>AUC_{last}$

AUC inf = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

F = Bioavailability, absolute bioavailability

** END OF REPORT **

^d WinNonlin Version 1.0 (Scientific Consulting Inc., 1995); Best fit is two compartmental which simultaneously solves iv and oral data sets. Analyzed using compartmental modeling techniques with established models or models written to simultaneously solve iv (Study V) and oral data sets (Study X) using 1/YHAT weighting where YHAT is the predicted plasma HMBP concentration at a given time.